"I love MPM Capital - Powering Breakthroughs in Life Sciences"

2022-05-08 13:55:33

Investor Login Home AboutCompaniesTeamContactPress MPM InvestingEarly‐stage investments to deliver breakthrough therapies across major therapeutic areas, with a focus on oncology Learn More About Our FocusMPM Capital is a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in companies that seek to translate scientific innovations into cures for major diseases. With its world-class team and deep experience in scientific research, clinical development, and company-building, MPM strives to power novel medical breakthroughs that transform patients’ lives. MPM invests across the biotech landscape with early-stage venture capital funds, and with impact and public equities products through its affiliate BioImpact Capital. Focus Area All Oncology Other Investments Current Exited Exit Type All IPO M&A 23andMeGenetic reports for consumers to better appreciate their ancestry OtherExited 28-7Small-molecule therapeutics that modulate miRNAs for treatment OncologyCurrent Affymax, Inc.Previously committed to developing novel drugs OtherExited AiresClinical stage pharmaceutical company for pulmonary disorders OtherExited Alinea Pharmaceuticals, Inc.Previously developed new treatments for metabolic conditions OtherExited Allozyne, Inc.Cancer and inflammatory disease therapeutic company OtherExited AlnaraOrally-delivered protein therapeutics to treat metabolic diseases OtherExited AmphivenaDeveloping bispecific TandAbs as a novel immunotherapy for hematological disorders OncologyCurrent AntheraDeveloping drugs for autoimmune diseases OtherExited Archus Orthopedics, Inc.Previously developed implants to treat spine disorders OtherExited ARYx Therapeutics, Inc.Previously focused on molecular design OtherExited Astute MedicalImproving the diagnosis of high-risk medical conditions OtherExited Atkis OncologyAktis Oncology is a biotechnology company pioneering targeted radiopharmaceuticals OncologyCurrent Atopix Therapeutics, Inc.Developing novel treatments for asthma OtherExited Barrier Therapeutics, Inc.Specialized in dermatological creams and gels OtherExited BioInterveneFirst-in-class target for the treatment of neuropathic pain OtherCurrent Blade TherapeuticsA discovery stage company focused on developing fibrosis treatments OtherCurrent CelladonDeveloping a transformative therapy for heart failure OtherExited Cellerant Therapeutics, Inc.novel immunotherapies for oncology and blood-related disorders OncologyExited Cerecor Inc.Developing innovative treatments for patients with CNS disorders OtherExited Ceregene, Inc.Development and manufacturing of gene therapies OtherExited Cerimon Pharmaceuticals, Inc.Developed and commercialized therapeutics for autoimmune diseases OtherExited CHF Solutions, Inc.Manufactures medical devices for cardiac care. OtherExited ChiasmaDeveloping oral drugs that were previously only available by injection OtherCurrent Clinical inkModernize clinical trials with eSource & patient engagement tools OtherExited Coda BiotherapeuticsChemogenetic neuromodulation platform to treat neurological disorders. OtherCurrent ConatusDeveloping novel therapeutics for liver diseases OtherExited CoStimDeveloping novel antibodies for cancer immunotherapy OncologyExited CoTherix, Inc.Licensing of therapeutic products for cardiopulmonary diseases OtherExited Cullinan OncologyCreating high-value cancer therapies using modern-day portfolio manage OncologyCurrent DigiTx PartnersDigiTx Partners is a digital health investment formed in partnership with Astellas Pharma OtherCurrent Dragonfly Sciences, Inc.developing a new class of biosimilar products OtherExited Dyne TherapeuticsDeveloping a pipeline of RNA-based therapeutics for neuromuscular disorders OtherCurrent EKR TherapeuticsProvides acute-care specialty products OtherExited ElevateBio, LLCBuilding a broad portfolio of cell and gene therapy companies OncologyCurrent Elixir Pharmaceuticals, Inc.Develops novel pharmaceuticals for the treatment of metabolic diseases OtherExited EndoGastric Solutions, Inc.Endoluminal treatment of gastroesophageal reflux disease OtherExited EndologixProvides optimal solutions for endovascular aortic repair OtherExited EnteroMedics, Inc.developer of vBloc® neurometabolic therapy OtherExited Entrada TherapeuticsDeveloping intracellular biologics for diseases with limited or no treatment options OtherCurrent EpizymePersonalized therapeutics for patients with genetically defined cancer OncologyExited ForteBioDevelops analytical systems that enable real-time analysis of biomolecular interactions OtherExited Frontier MedicinesDeveloping novel medicines to drug previously considered “undruggable” targets OncologyCurrent Harpoon TherapeuticsT cell redirecting antibodies for durable remissions in cancer OncologyCurrent Helicos Biosciences CorporationGenetic analysis for the research, drug discovery and diagnostics OtherExited Hypnion, Inc.development of novel therapeutics for (CNS) disorders OtherExited IconicDeveloping therapeutics for serious eye disorders OncologyOtherCurrent IDUN Pharmaceuticals, Inc. OtherExited Innovative Spinal Technologies, Inc.Developed treatments for spinal disorders OtherExited Intercell AGModern prophylactic and therapeutic vaccines OtherExited Intracel Holdings CorporationDevelopment and commercialization of cancer vaccines OncologyExited IOmx Therapeutics AGTargeting T cell evasion to treat cancer OncologyCurrent iPierianDeveloping anti-Tau protein antibodies for neurodegenerative disease OtherExited iTeos TherapeuticsNext-gen immuno-oncology therapies for both hot and cold tumors OncologyCurrent KaloBios Pharmaceuticals, Inc.developing monoclonal antibodies for cancer care OncologyExited MacroGenics, Inc. OncologyExited Maverick Therapeutics, Inc. Inducible T cell-redirecting antibodies for cancer OncologyExited Memory Pharmaceuticals Corp.Developed drug candidates for the treatment of CNS disorders OtherExited Meritage PharmaTreatment for eosinophilic esophagitis (EoE) OtherExited MitobridgeDiscovers and develops novel drugs that enhance mitochondrial function OtherExited Motus Therapeutics, Inc.Developing therapies for severe gastric mobility disorders OtherExited NeosilManufactures dermatology-focused specialty pharmaceutical products OncologyExited NeoVista, Inc.Technologies for age related mucular degeneration OtherExited NeuroMed Pharmaceuticals, Inc.Produces pain therapies in the US OtherExited NevroDeveloping a high-frequency stimulation technology for chronic pain OtherExited NextPointTherapies against immune checkpoints have revolutionized the treatment of cancer patients. OncologyCurrent OncorusDeveloping a next-generation immunotherapy platform to treat cancer OncologyCurrent OrnaDesigning and delivering a new class of fully engineered circular RNA (oRNA) therapeutics OtherCurrent Oxagen LimitedA privately-held biopharmaceutical company OtherExited PaciraAcute care products including EXPAREL for post-surgical analgesia OtherExited PeplinProducts for the treatment of cancer OncologyExited Peptimmune, Inc.Designs peptides for therapeutics, diagnostic kits & antibodies OtherExited PharmassetDiscovering and developing novel drugs to treat viral infections OtherExited PharmAthene, Inc.Acquire and develop products identified as urgent priorities OtherExited Poniard Pharmaceuticals, Inc.Discovery, development and commercialization of oncology products OtherExited Portola Pharmaceuticals, Inc.A biopharmaceutical company in the hematologic diseases fields OtherExited Potenza TherapeuticsDeveloping novel immunotherapies for the treatment of cancer OncologyExited ProtegoSmall molecule protein folding correctors for amyloid driven disorders. OtherCurrent Proteon TherapeuticsDeveloping a therapy to improve dialysis vascular access OtherExited QuatRx Pharmaceuticals CompanyTreatment of moderate to severe dyspareunia FDA approved in Feb 2013 OtherExited Radius HealthNovel, differentiated therapeutics for patients with osteoporosis OtherExited Raze TherapeuticsDeveloping novel anti-tumor agents through mitochondrial one-carbon me OncologyExited ReCodeIntegrated genetic medicines company OtherCurrent Repare TherapeuticsTargeting genetically-defined cancer weaknesses OncologyCurrent RhythmDeveloping peptide therapeutics for metabolic diseases OtherCurrent Rigel Pharmaceuticals, Inc.Small-molecule development for inflammatory and autoimmune diseases OncologyExited Rinat Neuroscience Corp.Develops treatment of diseases and disorders of the nervous system OtherExited SAIDrug discovery, development, and manufacturing services OtherExited SelexysDeveloping novel products to treat inflammatory diseases OtherExited Semma TherapeuticsDeveloping cell-based transformative therapies for diabetes patients OtherExited Sideris Pharmaceuticals, Inc.Development of new treatments for transfusion related iron overload OtherExited SiO2 Medical ProductsNovel materials science technology for pharmaceutical, lab and diagnostic products OtherCurrent SolasiaDeveloping, commercializing oncology & oncology supportive care drugs OncologyExited Somaxon Pharmaceuticals, Inc.Developed Silenor for treatment of insomnia OtherExited Surface Logix, Inc.Enhancing molecular functionality of pharmaceuticals OtherExited SyndaxDeveloping and commercializing epigenetic therapies for cancer OncologyExited TCR2, Inc.Focused on engineering T cells for cancer therapy OncologyCurrent Tercica, Inc.Developed Increlex for treatment of primary IGF-1 deficiency OtherExited Tetherex PharmaceuticalsOperates in the healthcare industry focusing on biotechnology business OtherCurrent Theraclone Sciences, Inc.Screening technology for antibodies that ward off disease OtherExited Tizona Therapeutics, Inc.Regulatory T cell suppression as a novel approach to fighting cancer OncologyCurrent TriNetXPlatform to improve clinical research, study design & recruitment OtherExited Triplet TherapeuticsDeveloping novel therapies for triplet repeat disorders OtherCurrent TrishulaDeveloping a first-in-class anti-CD39 antibody for treating cancer. OncologyOtherCurrent True North TherapeuticsDeveloping drugs which selectively inhibit the complement system OtherExited Turmeric Acquisition Corp.Turmeric Acquisition Corp. is a special purpose acquisition company (SPAC). Current UmojaRetool a patient’s immune system in vivo OncologyCurrent Vaccinogen, Inc.Personalized vaccines to fight disease OncologyOtherExited ValeritasMarketing a disposable insulin delivery device OtherExited VascularDeveloping a novel antibody for diabetic nephropathy OtherExited Verastem, Inc.Treating cancer by the targeted killing of cancer stem cells OncologyExited Verus Pharmaceuticals, Inc. Pediatric-oriented specialty pharmaceutical company OtherExited VLST CorporationNovel therapeutics for autoimmunity and inflammation OtherExited Werewolf TherapeuticsNovel immunotherapies that act selectively to enhance immune responses to cancer OncologyCurrent Xanodyne Pharmaceuticals, Inc.Integrated specialty pharmaceutical company OtherExited Role All Investment and Operations Team Executive Partners and Advisors Medical and Scientific Advisory Board Location All Cambridge San Francisco Patrick A. Baeuerle Patrick A. Baeuerle, Ph.D.Executive PartnerCambridge Read Bio Chris Bardon Christiana Bardon, M.D., M.B.A.Investment TeamCambridgeRead Bio Thomas M. Barnes Thomas M. Barnes, Ph.D.Executive PartnerCambridge Read Bio Pankaj Bhargava Pankaj Bhargava, M.D.Executive PartnerSan Francisco Read Bio Detlev Biniszkiewicz Detlev Biniszkiewicz, Ph.D.Executive PartnerCambridge Read Bio Stephen Blacklow Stephen C. Blacklow, M.D., Ph.D.MSABCambridge Read Bio Jeff Crispen Jeff CrispenFinance, Compliance and Operations Cambridge Read Bio Stephen Curtis Stephen Curtis, Ph.D.Investment TeamCambridge Read Bio Christian Desmarteaux Christian Desmarteaux, M.B.A.Investor Relations and MarketingCambridge Read Bio Thomas Ebeling Thomas EbelingAdvisorRead Bio Luke Evnin Luke Evnin, Ph.D.Investment TeamSan Francisco Read Bio Mitchell Finer Mitchell H. Finer, Ph.D.Executive PartnerCambridge Read Bio Todd Foley Todd Foley, M.B.A.Investment TeamCambridge Read Bio Ansbert Gadicke Ansbert Gadicke, M.D.Investment TeamCambridge Read Bio Brian Goodman Brian Goodman, Ph.D.Investment TeamCambridge Read Bio William Greene William Greene, M.D.AdvisorSan Francisco Read Bio William Hahn William C. Hahn, M.D., Ph.D.MSABRead Bio David Hallal David HallalAdvisorCambridge Read Bio Dan Hicklin Dan Hicklin, Ph.D.AdvisorCambridge Read Bio Robert Horvitz H. Robert Horvitz, Ph.D.MSABRead Bio Ed Hurwitz Ed Hurwitz, J.D., M.B.A.Investment TeamSan Francisco Read Bio Alim Ladha Alim Ladha, Ph.D.Investment TeamCambridge Read Bio Kristen Laguerre Kristen Laguerre, M.B.A.Finance and OperationsCambridge Read Bio Terri Lee Terri Lee, Ph.D.Investment TeamSan Francisco Read Bio Briggs Morrison Briggs Morrison, M.D.Executive PartnerCambridge Read Bio Kellie Neville Kellie NevilleInvestor Relations and MarketingCambridge Read Bio Gary Patou Gary Patou, M.D.AdvisorSan Francisco Read Bio Geraldine Paulus Geraldine Paulus, Ph.D.Investment TeamCambridge Read Bio Devin Quinlan Devin Quinlan, Ph.D.Investment TeamCambridge Read Bio Rami Rahal, Ph.D. Rami Rahal, Ph.D.Investment TeamCambridge Read Bio Matthew Roden Matthew Roden, Ph.D.Executive PartnerCambridge Read Bio David Ryan David P. Ryan, M.D.MSABRead Bio Uciane Scarlett Uciane Scarlett, Ph.D.Investment TeamCambridge Read Bio Andrew Scharenberg Andrew M. Scharenberg, M.D.Executive PartnerSan Francisco Read Bio Greg Sieczkiewicz Greg Sieczkiewicz, J.D., Ph.D.Executive Partner & Chief IP CounselCambridge Read Bio Pete Smith Pete Smith, Ph.D.Executive PartnerCambridge Read Bio Elizabeth Stoner Elizabeth Stoner, M.D.Executive PartnerCambridge Read Bio Wendy Young, Ph.D. Wendy Young, Ph.D.Executive PartnerSan Francisco Read BioContact UsThe San Francisco office has moved 1 mile north to Brisbane to the location shown [email protected] Cambridge, MA 450 Kendall StreetCambridge, MA 02142Phone | 617-425-9200 Get directions Brisbane, CA 2000 Sierra Point Parkway, Suite 701Brisbane, CA 94005Phone | 650-553-3300 Get directions Print Terms Of Use & Disclosures2022March 8, 2022AACR and MPM Oncology Charitable Foundation Announce Two Grants to Support Transformative Cancer ResearchMarch 5, 2022Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217January 6, 2022Top Life Sciences Startups to Watch in 2022January 6, 2022FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer2021December 16, 2021Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 PatientsDecember 7, 2021MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment CommitteeNovember 17, 2021Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding DiseasesOctober 29, 2021Entrada Therapeutics Announces Pricing of Upsized Initial Public OfferingOctober 22, 2021ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 MillionOctober 19, 2021Future Returns: MPM Capital’s Second Oncology Impact Fund Goes Beyond CancerOctober 18, 2021A single patient is producing insulin after treatment with Vertex’s new diabetes cell therapyOctober 18, 2021MPM Advisor Bill Hahn elected to the National Academy of MedicineOctober 11, 2021Listen to Thomas Barnes, Chief Executive Officer of MPM Company ORNA, on Pioneering circular oRNA therapeuticsOctober 6, 2021MPM Capital Raises Biotech’s Largest Impact Investment Fund to Help Finance the Fight Against Cancer and Other DiseasesOctober 1, 2021The Next RNA Breakthrough? Maybe Bending Strands Into CirclesSeptember 30, 2021MPM’s Chris Bardon Speaks on CNBC’s Delivering AlphaSeptember 23, 2021MPM Strengthens its Team with the Addition of Accomplished Biotech Executive and Drug Discoverer Wendy Young, PhDSeptember 21, 2021MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhDAugust 30, 2021From bench to boardroom: 20 of the most influential biopharma R&D executives in drug developmentJuly 8, 2021Burrage Capital Joins Forces With MPMJune 21, 2021Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the ClinicJune 14, 2021GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology raceJune 14, 2021iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinationsJune 4, 2021iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021May 25, 2021These are the 2021 CNBC Disruptor 50 companiesMay 7, 2021Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with AmrytMay 3, 2021Werewolf Therapeutics Announces Pricing of Upsized Initial Public OfferingApril 13, 2021Pankaj Bhargava was a central figure in the group fashioning Gilead’s oncology strategy. Now he’s jumped to the VC side and the next-gen game at Dana-FarberApril 13, 2021MPM Capital Adds to Senior Team with the Appointment of Oncology Leader Pankaj Bhargava, MD as Executive PartnerMarch 31, 2021Entrada Therapeutics Announces Closing of $116 Million Series B FinancingMarch 18, 2021Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid TumorsMarch 18, 2021Are radiopharmaceuticals ready for the mainstream? Novartis, Bristol Myers Squibb bet yes on MPM’s platform takeMarch 15, 2021ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C FinancingMarch 11, 2021Future Returns: How UBS Surpassed a $5 Billion Impact GoalMarch 9, 2021Takeda to Acquire Maverick TherapeuticsFebruary 24, 2021Orna Therapeutics Launches with over $100M Raised to Develop a New Class of Fully Engineered Circular RNA TherapiesFebruary 24, 2021The mRNA era is here. MPM believes the future belongs to oRNA- and Big Pharma wants a seat at the tableJanuary 20, 2021TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common StockJanuary 19, 2021AACR and MPM Oncology Charitable Foundation Announce Three Grants to Support Transformative Cancer ResearchJanuary 8, 2021Cullinan Management Announces Pricing of Upsized Initial Public Offering (CORRECTION)January 7, 2021Werewolf Therapeutics Completes $72 Million Series B FinancingJanuary 5, 2021MPM Capital Announces the Promotions of Shinichiro Fuse, Ph.D. and Kristen Laguerre to its Investment Committee2020December 18, 2020Cullinan Oncology Completes $131.2 Million Series C FinancingDecember 13, 2020TCR² ANNOUNCES RECIST RESPONSE IN OVARIAN CANCER FROM ONGOING PHASE 1/2 TRIALDecember 8, 2020Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development ProgramsNovember 30, 2020Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™November 19, 2020Umoja Biopharma Raises $53M in Series A FinancingOctober 2, 2020ONCORUS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERINGSeptember 29, 2020MPM joins the historic SPAC boom as its blank check company files for an IPOSeptember 18, 2020Roden, fresh from BMS-Celgene merger, lands VC role at MPMSeptember 17, 2020MPM Capital Bolsters Senior Team with Appointment of Matthew Roden as Executive PartnerSeptember 17, 2020After leading Celgene buyout, Matthew Roden leaves Bristol Myers Squibb for venture capital firmSeptember 16, 2020Dyne Therapeutics Announces Pricing of Initial Public OfferingAugust 11, 2020DYNE THERAPEUTICS ANNOUNCES $115 MILLION FINANCING TO ADVANCE PIPELINE OF MODERN OLIGONUCLEOTIDE THERAPEUTICS FOR SERIOUS MUSCLE DISEASESJuly 30, 2020AlloVir Announces Pricing of Upsized Initial Public OfferingJuly 28, 2020TCR² THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCKJuly 24, 2020iTeos Therapeutics Announces Pricing of Initial Public OfferingJuly 21, 2020Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 MillionJuly 16, 2020Oncorus Announces Clinical Trial Collaboration with MerckJune 27, 2020Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin AnalogJune 23, 2020Repare Therapeutics Announces Pricing of Upsized Initial Public OfferingJune 6, 2020Cullinan Oncology Completes $98.5 Million Series B FinancingJune 1, 2020After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPOMay 28, 2020Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers SquibbApril 1, 2020iTeos Therapeutics Closes $125 Million Series B2 FinancingMarch 31, 2020ElevateBio Closes $170 Million Series B FinancingMarch 30, 2020ReCode Therapeutics Raises $80 Million In Oversubscribed Series A FinancingFebruary 26, 2020MPM Capital Announces $100M Oncology Innovations Fund as Part of Novel Venture Philanthropy Collaboration with Dana-Farber Cancer InstituteFebruary 26, 2020WSJ.com – MPM Capital Raises $100 Million Fund, Teams Up With Dana-Farber Cancer InstituteFebruary 26, 2020FierceBiotech – MPM gains first offer on Dana-Farber tech, raises $100M fundFebruary 26, 2020Endpoints News – Tying basic science to spinouts, Dana-Farber debuts sister funds totaling $126M with MPM CapitalFebruary 24, 2020AACR to Receive $2 Million to Support Innovative Research from UBS Oncology Impact Fund Managed by MPM CapitalFebruary 12, 2020AlloVir Receives the European Medicines Agency PRIME Designation for Viralym-M, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T-Cell TherapyFebruary 7, 2020Dyne Therapeutics Expands Leadership Team with Key HiresFebruary 5, 2020CODA Biotherapeutics Acquires Attenua and Three Clinical Stage AssetsJanuary 30, 2020iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon RegionJanuary 23, 2020Epizyme Receives FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Epithelioid SarcomaJanuary 6, 2020BioIntervene Announces $30 Million Series A Financing2019December 17, 2019The AACR-MPM Oncology Charitable Foundation Announces First Grants to Support Transformative Cancer ResearchDecember 17, 2019Triplet Therapeutics Launches with $59 Million in Financing to Further Its Development of Transformative Treatments for Triplet Repeat DisordersNovember 21, 2019Harpoon Therapeutics and AbbVie Announce Licensing and Option Collaboration to Advance HPN217, Harpoons’ BCMA-Targeting TriTAC®, and Expand Existing Discovery CollaborationOverall Deal Potential Valued up to $2.4B November 20, 2019Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer MedicinesNovember 18, 2019Novartis and MPM Capital Invest in SiO2 Medical Products Developing a Potentially Disruptive Novel Packaging TechnologyNovember 15, 2019New Novartis Medicine Adakveo® (crizanlizumab) Approved by FDA to Reduce Frequency of Pain Crises in Individuals Living with Sickle Cell DiseaseTherapy developed by MPM portfolio company Selexys, acquired by Novartis in 2016November 5, 2019CODA Biotherapeutics Announces Series A Extension, Bringing Total Round to $34MOctober 16, 2019Rhythm Pharmaceuticals, Inc. Announces Pricing of Public OfferingOctober 8, 2019MPM’s Todd Foley Comments on Pharma Market in WSJ Pro VC “Pharma Mergers, Strong IPO Market Mute Startup Acquisitions”October 7, 2019TriNetX Named Technology Partner for FDA Sentinel SystemSeptember 25, 2019Blade Therapeutics Expands Anti-Fibrotic Pipeline With Acquisition of ATXCoSeptember 24, 2019MPM Capital Executive Partner Patrick Baeuerle Wins 2019 Xconomy “X of the Year” AwardSeptember 24, 2019Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement PortfolioSeptember 23, 2019MPM Capital Portfolio Company Frontier Medicines Honored with a Fierce 15 AwardSeptember 4, 2019MPM’s Todd Foley Discusses Acquisition of Semma Therapeutics in WSJ Pro VC “Vertex Makes Another Aggressive Purchase With Semma”September 4, 2019Repare Therapeutics Announces US$82.5 Million Series B FinancingSeptember 3, 2019Semma Therapeutics to be Acquired by Vertex for $950MAugust 22, 2019Iconic Therapeutics Signs Ophthalmology Option Agreement with NovartisAugust 21, 2019Oncorus Announces $79.5 Million Series B Financing to Support the Advancement of Oncolytic Virus Therapies to Transform Outcomes for Cancer PatientsJuly 26, 2019Chiasma Announces Pricing Of Underwritten Public Offering Of $55.0 Million Of Common StockJuly 26, 2019MGH and ElevateBio Announce a 10-Year Alliance Agreement to Utilize ElevateBio BaseCamp to Manufacture Innovative Cell and Gene TherapiesJune 25, 2019Frontier Medicines Launches with $67M Series A FinancingDeveloping novel medicines that drug previously considered “undruggable” targets, starting with cancerMay 22, 2019Portfolio Company ElevateBio Announces that Allovir Joins its Portfolio of Highly Innovative Cell and Gene Therapy CompaniesMay 16, 2019Iconic Therapeutics And Exelixis Enter into Exclusive Option and License Agreement for Novel Antibody-drug Conjugate ProgramMay 13, 2019ElevateBio Launches to Create and Operate a Portfolio of Highly Innovative Cell and Gene Therapy Companies$150M Series A financing co-led by UBS Oncology Impact Fund Managed by MPM CapitalApril 26, 2019Aratana Therapeutics to be Acquired by Elanco Animal HealthApril 3, 2019AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program Now Inviting ApplicationsApril 3, 2019Dyne Therapeutics Launches with $50 Million Series A to Develop Targeted Therapies for Muscle DiseasesMarch 13, 2019TriNetX Secures $40 Million in Series D FundingFebruary 22, 2019MPM’s Patrick A. Baeuerle Awarded the 2019 Lennart Philipson Award for Contributions to Cancer ImmunotherapyFebruary 22, 2019BioCentury: MPM Keeps BuildingLuke Evnin speaks with Chris Lieu at BioCentury (full article - subscription)February 21, 2019The Wall Street Journal: Biotech Investor MPM Capital Refuels With $400 Million Venture FundAnsbert Gadicke speaks with Brian Gormley at the Wall Street Journal (full article -subscription)February 21, 2019Scrip Pharma intelligence: MPM Raises $400M To Build Early-Stage BiotechsAnsbert Gadicke speaks with Kevin Grogan at Scrip Pharma intelligence (full article -subscription)February 21, 2019Endpoints News: MPM Adds $408M for its Next Big Wave of Biotech Startups — and Oncology Still Dominates the MenuLuke Evnin speaks with John Carroll at Endpoints NewsFebruary 21, 2019MPM Capital Raises $400 Million to Fund Early-Stage Biotech InnovationFebruary 20, 2019Harvard Business Review: Impact Investing Could Accelerate the Fight AgainstUBS Oncology Impact Fund managed by MPM cited as a “..model other funds could emulate..” January 3, 2019Tizona Therapeutics Appoints Scott Clarke as Chief Executive Officer and Provides Update on Regulatory Milestone for its First-in-Class CD39 program in CancerJanuary 3, 2019Tizona Therapeutics and AbbVie Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD392018December 18, 2018Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics PlatformSeries A co-led by 5AM Ventures and MPM Capital, along with other top investorsNovember 29, 2018TCR2 Therapeutics wins U.S. Private Company of the Year Award at LifeStars Awards™ Life Sciences 2018 EventNovember 12, 2018Harpoon Therapeutics Announces Closing of $70M Series C FinancingSeptember 25, 2018Verastem Oncology Receives FDA Approval of COPIKTRA™ (duvelisib) CapsulesTreatment for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapiesSeptember 13, 2018MPM Capital Expands its Team of Executive Partners and Entrepreneurs with the Appointments of Biotech Leaders Detlev Biniszkiewicz and Scott ChappelSeptember 12, 2018MPM Capital and Versant Ventures Launch CODA Biotherapeutics to Accelerate Development of Chemogenetic Gene Therapy PlatformIndustry veteran Michael Narachi joins as President and CEO September 6, 2018Twentyeight-Seven Therapeutics Launches with a $65 Million Series A FundingAugust 6, 2018Harpoon Therapeutics Treats First Patient With HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) PatientsHPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA)August 1, 2018Oncorus®, Inc., Names Industry Veteran Ted Ashburn as new President and CEO– Company co-founder Mitch Finer named new Chairman of the Board –July 18, 2018Maverick Therapeutics Advances Technology; Adds Key ManagementJames R. Vasselli MD to Lead Clinical DevelopmentJune 27, 2018MPM Executive Partner, David Hallal, Appointed Chairman of iTeos TherapeuticsJune 26, 2018Patrick Baeuerle, MPM Executive Partner and Immunotherapy Pioneer, to Present Compelling Data from Harpoon Therapeutics’ Biotherapeutics Platform at the 2018 European Congress on BiotechnologyJune 20, 2018MPM Leads $75 Million Series B Financing of iTeos TherapeuticsMay 29, 2018Chris Bardon Talks to WSJ Pro VC about Late-Stage Combination Therapy TrialsMay 22, 2018MPM Cancer Research Partnership with AACR Featured in Medpage TodayAACR Ventures into New Cancer Research Funding Model—Adapting model pioneered by Cystic Fibrosis FoundationMay 10, 2018MPM Portfolio Company Semma Therapeutics Appoints Bastiano Sanna, Ph.D. as CEO and PresidentMay 5, 2018Chris Bardon Comments to Reuters on the OIF and its Philanthropic ImpactRead: “Executive Perspective: An example of innovative impact investing from UBS”May 2, 2018Watch Now: Chris Bardon is a Featured Panelist at Paying for Cures – Global Conference 2018 | Milken InstituteApril 23, 2018MPM’s Approach to Investing is Positively Impacting Cancer Research and CareLearn more in BioWorld article, “Socially Conscious Investing Benefits AACR, UBS’ Optimus”April 19, 2018MPM’s Partnership with AACR Highlighted in WSJ Pro VC “Gormley’s Take: Health-Care Investors Doing Good After Doing Well”April 18, 2018MPM Capital Portfolio Company Tetherex Pharmaceuticals Completes $50M Series B FinancingApril 16, 2018MPM and AACR Announce Partnership in Cancer ResearchApril 16, 2018Watch Now: Press Event Announcing MPM and AACR Partnership in Cancer ResearchPanel from AACR, MPM and UBS Discuss First Funding Gift from UBS Oncology Impact Fund managed by MPMApril 16, 2018MPM and AACR Partnership Featured in Barron’s Article “UBS Oncology Impact Fund Announces $2.5M in Gifts”April 15, 2018Watch Now: Chris Bardon Announces MPM and AACR Partnership in Cancer Research at AACR 2018 Opening CeremonyApril 9, 2018MPM’s Chris Bardon Comments on Lessons Learned from Recent IO Trial ResultsRead BioWorld article “Epacadostat/Keytruda Pivotal Trial Flop Sends Shivers Down IDO Pathway”March 21, 2018MPM Portfolio Company TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B FinancingFebruary 20, 2018Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based TherapeuticsJanuary 24, 2018Astellas Completes Acquisition of Mitobridge, Inc.January 11, 2018BioWorld’s Key Highlights from the Women in Bio and Bloomberg Intelligence Panel with Chris Bardon at JPM18“Women Have Their Say as All-Female Panel Talks Biopharma Investment, Technology Trends” January 10, 2018Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast CancerJanuary 9, 2018WATCH NOW: Chris Bardon Discusses the Cycle of Innovation and Value of Transformative Therapies on CNBCJanuary 9, 2018Rhythm Pharmaceuticals Enters into Partnership with WuXi NextCODE the Emerging Global Standard Platform for Genomic DataThe partnership will help Rhythm identify genetic markers for rare metabolic syndromes and optimize investigational compoundsJanuary 8, 2018Chris Bardon Shares her Thoughts on Market Trends and Innovative Therapies with BioWorld“‘Spirit’ of JPM Lives on as Other Meetings Muscle in on Biopharma Playground”January 3, 2018TCR2 Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference2017December 9, 2017Chris Bardon Comments on Positive Gene Therapy Data in Forbes article, “Excitement Builds Around Gene Therapy Cures For Hemophilia”December 1, 2017MPM portfolio company, Mitobridge, Inc. to be acquired by Astellas Pharmaceuticals in a deal worth up to $450 millionNovember 30, 2017Semma Therapeutics Raises $114m for Novel Diabetes TreatmentOctober 19, 2017Syndax Expands Pipeline with Exclusive Worldwide License to Allergan’s Portfolio of Menin-MLL InhibitorsOctober 19, 2017TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical OfficerOctober 19, 2017Blade Therapeutics Announces Selection of a Clinical Development Candidate and Funding of the Second Tranche for its Series B FinancingOctober 18, 2017AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research CollaborationOctober 17, 2017Mitobridge featured in Bloomberg article, “One Scientist’s Marathon Quest for the Exercise Pill”October 4, 2017Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public OfferingOctober 3, 2017Oncorus®, Inc., Names Christophe Quéva, Ph.D., as Chief Scientific OfficerOctober 3, 2017The UBS Oncology Impact Fund Co-leads $150 Million Series A Financing of Cullinan OncologyCullinan Oncology is an Innovative Development Company with an Accomplished Management Team to Develop Pipeline of Novel Cancer TherapiesSeptember 26, 2017Repare Therapeutics Named as One of FierceBiotech’s “Fierce 15” Biotech Companies of 2017September 16, 2017Inside Perspectives on Gene Editing: An Interview with MPM Capital’s Mitchell FinerSeptember 15, 2017TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology FrontiersSeptember 13, 2017Oncorus’ Viral Cancer Vaccine Highlighted in WSJ: “Scientists See Progress for Cancer Vaccines”September 5, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana BardonSeptember 1, 2017Gormley’s Take: Writing War on Cancer’s Next Chapter –– Biotech startups seek to widen benefits of revolutionary cell-therapy treatmentsWSJ Pro Venture Capital features MPM’s Chris Bardon and TCR2August 31, 2017MPM’s Chris Bardon Applauds Novartis’ Value-Based Pricing Move for its CAR-T Cell Therapy KymriahRead BioWorld article “Gene therapy, cloaked in cell therapy, arrives in U.S. courtesy of Kymriah”August 11, 2017Maverick Therapeutics Appoints James S. Scibetta as CEOJuly 27, 2017MPM’s Chris Bardon Talks to BioWorld About Recent Pharma R&D RestructuringTrends point to pharma focus on signing more early stage partnershipsJuly 17, 2017Radius Health Appoints Jesper Høiland as President and Chief Executive OfficerLeading the Next Stage Of Growth and Value Creation As A Fully Integrated Commercial Biotech CompanyJune 28, 2017Semma Therapeutics Mentioned in WSJ article “Biotech Startups’ Cell-Based Diabetes Attack”June 22, 2017MPM and Versant Venture Co-Lead Series A Financing of Repare TherapeuticsJune 21, 2017Proteon Therapeutics Announces $22.0 Million Private PlacementJune 20, 2017Visionary Scientist Stephen J. Elledge Joins MPM Capital’s Medical and Scientific Advisory BoardJune 13, 2017Accomplished Oncologist and Scientist William C. Hahn Joins MPM Capital’s Oncology Impact Fund Advisory BoardJune 8, 2017TCR2 Therapeutics to Debut Positive Solid Tumor Data on its Novel TRuC™ Engineered T Cell Platform at the World Preclinical CongressJune 6, 2017Radius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)May 25, 2017Amgen vet Patrick Baeuerle inspires a $45M round from A-list VCs for a next-gen I/O drug platformMay 25, 2017Harpoon Therapeutics Announces Completion of $45M Series B FinancingMay 23, 2017MPM Portfolio Company True North Therapeutics Acquired by Bioverativ, IncUpfront payment of $400M plus assumed cash, with additional payments of up to $425M contingent on the achievement of future milestonesMay 18, 2017Syndax Shares Soar as Lead Drug Clears a Mid-Stage Cancer Drug Study HurdleMay 4, 2017Conatus Announces Exercise of License Option for Global Development and Commercialization of Emricasan Following Notice of Initiation of Phase 2b ENCORE-LF Clinical Trial in NASH CirrhosisMay 3, 2017Inside Perspectives on Cancer Immunotherapy: An Interview with MPM’s Christiana BardonApril 28, 2017FDA Approves MPM Portfolio Company Radius Health’s TYMLOS™ (abaloparatide)Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for FractureApril 17, 2017Meet One the Most Successful German Biotech Leaders Ever Read more about MPM’s Patrick BaeuerleApril 5, 2017MPM Managing Director Chris Bardon Named a Top-40 TransformerTop innovation gurus leading the biopharma industry's transformation are recognized by MM&M April 4, 2017MPM Portfolio Company Oncorus Nominated for 2017 NEVY Award as Hottest Early-Stage Startup TherapeuticsApril 4, 2017Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of DirectorsFebruary 16, 2017Rhythm Announces Completion of $41 Million Mezzanine Financing— Proceeds to finance significant expansion of genetic obesity clinical trials —February 7, 2017Chris Varma, Co-founder and Former President and CEO of Blueprint Medicines, Joins MPM as Entrepreneur-in-ResidenceJanuary 11, 2017MPM Portfolio Company Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement TherapiesJanuary 5, 2017Accomplished Biotech Investor Ed Hurwitz Joins MPM as Managing Director2016December 19, 2016MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-TechneDecember 19, 2016Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.December 15, 2016Oncorus®, Inc. Announces Additional Series A Financing Support From Astellas Venture Management LLCDecember 13, 2016Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEODecember 8, 2016TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies- $44.5M Series A Financing Led by MPM Capital and F2 Ventures -December 2, 2016Chris Bardon, MPM Managing Director, Comments to Bloomberg on New Approaches to Medical PhilanthropyRead full article – “A Few Billionaires Are Turning Medical Philanthropy on Its Head” November 28, 2016Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Tumor Program UpdateNovember 21, 2016Novartis Acquires MPM Portfolio Company Selexys Pharmaceuticals Corporation and SelG1 Antibody for Reduction of Pain Crises in Sickle Cell DiseaseNovember 8, 2016Harpoon Therapeutics Appoints Hans-Peter Gerber, PhD, As Chief Scientific OfficerNovember 7, 2016Semma Therapeutics Announces Mark Fishman, M.D. Has Joined Its Board of Directors as ChairmanOctober 31, 2016MPM Portfolio Company Epizyme Expands Clinical Programs through Cooperative Research and Development Agreements with the National Cancer InstituteOctober 27, 2016Motus Therapeutics Inc., a Subsidiary of MPM Portfolio Company Rhythm Holding Co., LLC is to be Acquired by AllerganAcquisition Announced Following Positive Results for Phase 2b Clinical Trial of Treatment for GI DisordersOctober 13, 2016True North Therapeutics Receives FDA Orphan Drug Designation for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, Including Cold Agglutinin Disease (CAD)October 11, 2016Pacira Pharmaceuticals’ Kristen Williams is Honored as 1 of 15 “Fierce Women in Biopharma 2016”Learn why Kristen stands out among women in the industrySeptember 22, 2016iOmx Therapeutics Raises EUR 40 Million in Series A roundCompany establishes top-tier investor base consisting of MPM Capital, Sofinnova Partners, Wellington Partners and Merck VenturesSeptember 19, 2016Three MPM Portfolio Companies (Blade, Oncorus & Rhythm) Named to FierceBiotech’s “2016 Fierce 15” ListSeptember 19, 2016Radius Announces Publication of Additional Positive Results from the Phase 3 Active Trial of Osteoporosis TreatmentSeptember 14, 2016Tizona Therapeutics, Inc. Appoints George Golumbeski, Ph.D., to its Board of DirectorsAugust 16, 2016Osteoporosis, a Disease With Few Treatment Options, May Soon Have One More Read coverage in NY Times and in Press ReleaseAugust 15, 2016Aratana Secures Third FDA ApprovalAnimal pain drug expected to be available to veterinarians in the fall of 2016August 11, 2016Harvard Medical School Appoints MPM Medical and Scientific Advisory Co-Chair George Daley as New DeanRead more in The Boston GlobeAugust 10, 2016Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million InvestmentAugust 1, 2016Astellas and MPM Capital Launch DigiTx PartnersJuly 26, 2016MPM Portfolio Company Blade Therapeutics Featured in the San Francisco Business TimesThe July 19 article, “Taking it personally, cutting–edge biotech snags $45 million,” discusses the latest round of funding for Blade, a company focused on finding therapies for fibrotic disease, and MPM Co-Founder Luke Evnin’s personal commitment to the cause.July 21, 2016Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency ObesitySignificant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathwayJuly 20, 2016Former Bluebird Bio (BLUE) CSO Takes the Reins at Oncorus; Startup Launches with $57 Million Series AJune 16, 2016MPM Portfolio Company Semma Therapeutics Featured in Boston GlobeBoston-area hospitals have teamed up with the Harvard Stem Cell Institute and Semma Therapeutics to make personalized cell-based therapies and organize clinical trials.June 2, 2016Chris Bardon, Managing Director for the Oncology Impact Fund, on Bloomberg Capital MarketsDiscussing Advances in Cancer Therapies as the 2016 ASCO Annual Meeting Gets UnderwayMay 27, 2016TriNetX Enters into Collaboration with CelgeneAdvance Clinical Trial Design and Research for Next-Generation Medicines PlannedMay 18, 2016Aratana Therapeutics Granted FDA Approval of ENTYCE®First-of-its-Kind Ghrelin MimeticMay 3, 2016MPM Launches $471 Million Social Impact Oncology FundApril 29, 2016UBS Cancer Fund Shows Power of Impact InvestingA new oncology fund will finance academic research and access to cancer care in developing countriesApril 28, 2016UBS, MPM Seek Big ‘Impact’ in Cancer Drugs with $471M FundBy Marie Powers, BioWorld Today, April 28, 2016April 27, 2016UBS Raises Record $471 Million for Oncology Impact FundBioSpace.com 4/27/2016March 21, 2016Aratana Therapeutics Granted First FDA ApprovalGalliprant for the Control of Pain and Inflammation Associated with Osteoarthritis in DogsMarch 14, 2016Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with AcromegalyMarch 8, 2016Tizona Therapeutics, Inc., Completes $43 Million Series B FinancingMarch 6, 2016Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with OsteoporosisMarch 3, 2016Nasdaq Welcomes Syndax Parmaceuticals, Inc. to The Nasdaq Stock MarketJanuary 9, 2016Iconic Therapeutics Closes Series C Financing2015October 15, 2015Semma Therapeutics named FierceMedicalDevices’ 2015 Fierce 15August 27, 2015Syndax Enters Clinical Trial Collaboration in Cancer Immunotherapy Combining Entinostat and AtezolizumabAugust 24, 2015Syndax Raises $80 Million in Series C FinancingAugust 17, 2015Rhythm Subsidiary Raises $40 Million in Oversubscribed FinancingFinancing to advance Rhythm Metabolic, Inc.'s setmelanotide program for rare genetic disorders of obesityAugust 15, 2015Epizyme Appoints Robert Bazemore President and Chief Executive OfficerJuly 16, 2015Chiasma, Inc. Prices Initial Public Offering of Common StockJuly 10, 2015Taking Clinical Trials Out of the Dark Ages (Clinical Ink)June 23, 2015Briggs W. Morrison, M.D., CEO of Syndax, Appointed Key Strategic Advisor to MPM CapitalJune 15, 2015Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in AcromegalySubmission based on positive results from Phase 3 clinical trialJune 1, 2015K. Peter Hirth, PhD, Joins Iconic Therapeutics as Board Member and Senior Scientific AdvisorMay 21, 2015MPM Capital appoints Pablo J. Cagnoni, M.D., former Onyx Pharmaceuticals President, as Managing Director and CEO of MPM immunotherapy portfolio company VesuviusMay 14, 2015MPM closes $400 million fundMay 5, 201523andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.With Lupus Awareness Month Underway, Study Aims to Build a 5,000-Patient Lupus Cohort to Advance Understanding of the DiseaseApril 22, 2015Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of Immuno-oncology TherapeuticsExclusive Collaboration Includes Option for Astellas to Acquire PotenzaApril 15, 2015Novartis International Global Head M&A and Licensing Anthony Rosenberg to join as Managing Director, effective April 1, 2015- To serve as strategic advisor and on MPM portfolio boards to build leading companies -March 24, 2015Biotech Startup to Fight Diabetes on the Cellular FrontSemma Therapeutics seeks to turn success in stem research lab into a way to encourage insulin productionMarch 24, 2015Semma Therapeutics Announces $44 Million in Funding Led by MPM Capital to Develop Cell Therapy for Treating Type 1 Diabetes; Signs Agreement with Global Pharmaceutical CompanyMarch 16, 2015Ebb & Flow: Chiasma’s Private DecisionMarch 16, 2015Chiasma Announces Mark Leuchtenberger as Chief Executive OfficerProven Business Leader to Oversee Commercialization of Octreotide CapsulesMarch 12, 201523andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to LeadDr. Scheller Joins 23andMe’s Executive Leadership Team as Chief Science Officer and Head of TherapeuticsMarch 11, 2015MPM Capital Announces Immuno-Oncology Pioneer Patrick Baeuerle to serve as Managing Director-Top scientist and drug developer joins MPM senior team advancing breakthroughs and discoveries March 10, 2015Radius (RDUS) Announced Today That It Has Acquired The License To Develop And Market RAD1901 In JapanDinesh Purandare Hired (Former Sanofi (SAN.PA) Oncology Executive To The Position Of Senior Vice President (SVP) And Head Of Global Oncology At Radius )February 27, 2015Chiasma Announces Completion of $70 Million Series E FinancingFebruary 27, 2015Verastem Receives Orphan Drug Designation From FDA For VS-5584 In MesotheliomaFebruary 24, 2015Chiasma Appoints David Stack as Chairman of the Board; John A. Scarlett, M.D. Joins Board of DirectorsFebruary 20, 2015Syndax Says Immuno-oncology Discovery Happened Instead of an IPOFebruary 10, 2015Chiasma Inc. Releases Newly Published Phase 3 Study ResultsShow Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal DisorderFebruary 9, 2015Radius, Celladon and Nevro Among Top IPOs in 2014MPM has #1, 8 and 10 out of the top 14January 1, 2015Radius: The Top Performing IPO of 2014Radius, which is developing treatments for osteoporosis, is up 364% since pricing its June 6 initial public offering at 82014December 22, 2014Radius Announces Positive Phase 3 Top-Line ResultsDecember 15, 2014For Venture Capital, Biotech is Where It’s Really AtAugust 4, 2014Aratana Featured: Start-Ups Work on Biotech Drugs for PetsJune 17, 2014True North snags $22M and sets course for the clinic with a rare disease drugApril 29, 2014iPierian acquired by Bristol-Myers SquibbAdvances discovery strategy to pursue therapeutics for genetically defined diseasesApril 16, 2014Iconic Therapeutics Raises $20 Million to Advance Clinical Development of Wet AMD ProgramWilliam Greene, MD, Appointed Chief Executive OfficerApril 14, 2014Celladon Receives Breakthrough Therapy Designation from FDAMYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation from FDA’s Center for Biologics Evaluation and Research (CBER)February 18, 2014CoStim Pharmaceuticals, Inc. Acquired by NovartisJanuary 27, 2014MPM Capital and Kleiner Perkins Caufield & Byers top the list of investors with the most 2013 IPOsJanuary 7, 2014Epizyme and Celgene Advance EPZ-5676 DOT1L Inhibitor Clinical Program to Benefit Cancer Patients with Acute Leukemias, Achieving $25 Million Clinical Proof of Concept Milestone202220212020201920182017201620152014back to topCopyright © 2022 MPM Capital, Inc.XXX Please click here for all funds: Investor LoginX.modal_container .login_modal { display: inline-block; /*width: 50%;*//*left:25%;*/width: 100%; height: auto; margin: auto; top: 20%; background-color: #fff; padding: 20px; vertical-align: top; position: relative;background: url(/wp-content/themes/mpm-capital/images/background-dots.jpg) repeat; background-size: cover; background-position: center top;}#login-modal {z-index:999;}